Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Zydus announces data presentations on Saroglitazar for treating NASH, a liver disease, at the 2015 Keystone Symposia Conference on Liver Metabolism and Nonalcoholic Fatty Liver Disease (NAFLD) in British Columbia, Canada

 Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 06, 2015 titled "Zydus announces data presentations on Saroglitazar for treating NASH, a liver disease, at the 2015 Keystone Symposia Conference on Liver Metabolism and Nonalcoholic Fatty Liver Disease (NAFLD) in British Columbia, Canada".
06-02-2015
Bigul

The Ramanbhai Foundation 7th International Research Symposium Advances in New Drug Discovery and Development gets underway

 Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 02, 2015, titled "The Ramanbhai Foundation 7th International Research Symposium Advances in New Drug Discovery and Development gets underway".
02-02-2015
Bigul

Q3 results on Feb 10, 2015

 Cadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 10, 2015, inter alia, to consider & approve the unaudited financial results for the quarter and nine months ended on December 31, 2014 (Q3).Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 1992, the Trading Window will remain...
20-01-2015
Bigul

Cadila Healthcare Ltd reply to clarification sought by the exchange

 The Exchange had sought clarification from Cadila Healthcare Ltd with respect to news appearing in Business Standard on January 09, 2015 titled "Cadila recalls 19,536 bottles of cough treatment drug in US."Cadila Healthcare Ltd replied stating "The recall by our US subsidiary was voluntary and a class-II type recall. The Company does not envisage any material impact".
09-01-2015
Bigul

Clarification sought from Cadila Healthcare Ltd

 The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article appearing in Business Standard on January 09, 2015 titled "Cadila recalls 19,536 bottles of cough treatment drug in US."The reply is awaited.
09-01-2015
Bigul

Shareholding Pattern For December 31, 2014

 Cadila Healthcare Ltd has informed BSE about the Shareholding Pattern as on December 31, 2014.
07-01-2015
Bigul

Cadila Healthcare Ltd reply to clarification sought by the exchange

 The Exchange had sought clarification from Cadila Healthcare Ltd with respect to news appearing in Economic Times on December 31, 2014 titled "Wockhardt, Cadila & Hospira voluntarily recall drugs in US." Cadila Healthcare Ltd replied stating "the recall by our US subsidiary was voluntary and a class-III type recall, which means that the use of the product is not likely to cause any adverse health consequences. There is no material impact....
31-12-2014
Bigul

Clarification sought from Cadila Healthcare Ltd

 The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article appearing in Economic Times on December 31, 2014 titled "Wockhardt, Cadila & Hospira voluntarily recall drugs in US." The reply is awaited.
31-12-2014
Bigul

Updates

 Cadila Healthcare Ltd has informed BSE that during an interaction with a media person of the Company Chairman and Managing Director was asked about healthcare concerns caused by "Congo Virus" and "Ebola Virus" and he had responded by saying that group was developing vaccines for these diseases as a part of Company's vaccine development programme. There were no investment details shared during the interaction.
31-12-2014
Bigul

Abstract of interaction with press

 Cadila Healthcare Ltd has informed BSE regarding "Abstract of interaction with press".
29-12-2014
Next Page
Close

Let's Open Free Demat Account